UNASSIGNED: We studied adults with @entity3052 ( @entity3052 ) after haploidentical (n=192) and 8/8 HLA-matched unrelated donor (n=1982), transplantation. Data were obtained from the Center for International Blood and Marrow Transplant Research. Haploidentical recipients received @entity9909 (CNI), @entity6051 and post-transplant @entity786 for @entity2132 ( @entity2132 ) prophylaxis; 104 @entity1 received myeloablative and 88, reduced intensity conditioning regimens. Matched unrelated donor transplant recipients received CNI with @entity6051 or @entity1499 for @entity2132 prophylaxis; 1245 @entity1 received myeloablative and 737, reduced intensity conditioning regimens. In the myeloablative setting, day-30 neutrophil recovery was lower after haploidentical compared to matched unrelated donor transplants (90% versus 97%, p=0.02). Corresponding rates after reduced intensity conditioning transplants were 93% and 96%, (p=0.25). In the myeloablative setting, 3-month acute grade 2-4 (16% versus 33%, p<0.0001) and 3-year chronic @entity2132 (30% versus 53%, p<0.0001) were lower after haploidentical compared to matched unrelated donor transplants. Similar differences were observed after reduced intensity conditioning transplants, 19% versus 28%, (p=0.05) and 34% versus 52%, (p=0.002). Among @entity1 receiving myeloablative regimens, 3-year probabilities of overall survival were 45% (95% CI 36-54) and 50% (95% CI 47-53) after haploidentical and matched unrelated donor transplants (p=0.38). Corresponding rates after reduced intensity conditioning transplants were 46% (95% CI 35-56) and 44% (95% CI 0.40-47) (p=0.71). Although statistical power is limited, these data suggests that survival for @entity1 with @entity3052 after haploidentical transplantation with posttransplant @entity786 is comparable with matched unrelated donor transplantation.

Haploidentical transplant with post-transplant @entity786 versus matched unrelated donor transplant for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity9909 :: ('23523', 'Gene') :: ['calcineurin inhibitor'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['GVHD', 'graft-versus-host disease'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity6051 :: ('CHEBI:168396', 'Chemical') :: ['mycophenolate']
@entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukemia']
